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Paper II 
Page 1363, Table I, New York Heart Association class II/III in the control group should 
be “24/16”.
Paper III 
Page 1222, Table I, New York Heart Association class II/III in the control group should 
be “24/16” and Ejection fraction in the rehabilitation group should be “30  8%”. 
Page 1223, Table 2, workload (W) in the Control Group, Time 2, should be “7220”.
Abstract, page 1220, line 6-7 should be “The mean ejection fractions at baseline were 30 
 8% in the exercise group and 31  9% in the control group.” 
Accidentally, is “Rehabilitation Group” used in Table 1, (Characteristic) instead of 
“Exercise Group” as in the rest of the paper.
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INTRODUCTION 
 
Chronic heart failure 
Definition 
Chronic heart failure (CHF) has many causes and a complex pathophysiology. A 
universally agreed upon definition is not to be found 1. However, it can be defined as a 
progressive clinical syndrome in which the heart is unable to deliver enough blood to 
meet the demand of the peripheral organs, which results in symptoms of fatigue, dyspnea 
and fluid retention 2. Fatigue and dyspnea may lead to decreased physical activity and 
limit functional capacity and health related quality of life (HRQL). Fluid retention may 
lead to pulmonary congestion and peripheral edema. The key components of CHF, 
according to the latest guidelines from the European Society of Cardiology (ESC), are the 
following 3: 
• Symptoms typical of CHF: 
 dyspnea at rest or during exercise, fatigue, tiredness, ankle swelling 
 AND 
• Signs typical of CHF: 
 tachycardia, tachypnoea, pulmonary rales, pleural effusion, raised jugular venous 
 pressure, peripheral oedema, hepatomegaly      
 AND 
• Objective evidence of structural or functional abnormality of the heart at rest 
 abnormality on the echocardiogram, cardiomegaly, third heart sound, cardiac 
 murmurs, raised natriuretic peptide levels. 
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Objective assessment based on objective measures of cardiac structure and function (e.g., 
ECG, chest x-ray, echocardiography, radiologic imaging, stress testing) is important to 
evaluate cardiac status in CHF. However, it is well-known that the severity of symptoms 
for patients with CHF is not necessarily matched with the degree of impaired structure 
and the functional limitation. CHF is additionally quantified by the New York Heart 
Association (NYHA) functional classification 4 (Table 1). This classification is not exact, 
but remains the most widely used grading system of common symptoms in patients with 
CHF 5. 
 
Table 1. New York Heart Association (NYHA) functional classification of patients with 
chronic heart failure 
5
. 
NYHA class Symptoms One year mortality 
I No limitation of physical activity. 
Ordinary physical activity does not cause undue 
fatigue, palpitation, or dyspnea. 
5% 
II Slight limitation of physical activity. 
Comfortable at rest, but ordinary physical 
activity results in fatigue, palpation, or dyspnea. 
10-15% 
III Marked limitation of physical activity. 
Comfortable at rest, but less than ordinary 
activity results in fatigue, palpation, or dyspnoea. 
20-30% 
IV Unable to carry on any physical activity without 
discomfort. Symptoms at rest. 
If any physical activity is undertaken, discomfort 
is increased. 
35-50% 
 
 
 The cardiac natriuretic hormones (peptides), B-type natriuretic peptide (BNP) or 
amino terminal pro B-type Natriuretic Peptide (NTpro-BNP) are increased in patients 
with CHF. These peptides are increasingly used in the prognosis and diagnosis of patients 
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with CHF, and differentiate CHF patients from patients with non-cardiac causes of acute 
dyspnea 6. NT pro-BNP has emerged as a powerful circulating marker of cardiac function 
7,8. 
 
Prevalence, incidence and prognosis 
CHF is a major and increasing health problem, and one of the main causes of death in the 
western society 9, with a prognosis equal to many highly malignant tumors 10. The 
prevalence of CHF increases with age, from about 1-2 % in persons 25-75 years, up to 9-
20 % in persons > 75 years 3,11,12. CHF is the leading diagnosis for hospitalization of 
older adults 13. It has been estimated that the number of CHF cases will double in the next 
four decades 14,15. It seems like the prevalence of CHF is rising, because the incidence of 
older people in the population is increasing. In addition, improved treatment of coronary 
artery disease (CAD) means that more patients survive to develop CHF 16. 
 
Causes 
Almost all cardiac diseases can lead to CHF. The most frequent causes are often a long-
term outcome of diseases such as myocardial infarction secondary to CAD, hypertension, 
valvular disease, arrhythmias, myocarditis and cardiomyopathies 3. In addition, the 
syndrome can deteriorate due to e.g. anemia, thyrotoxicosis, cardiodepressant drugs and 
renal failure 4. 
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N-terminal pro B-type natriuretic peptide  
The cardiac natriuretic hormones are a family of related peptide hormones produced by 
cardiac myocytes 17. When released from cardiac myocytes, pro B-type peptide is cleaved 
into BNP and its N-terminal fragment, NT pro-BNP. BNP and NT pro-BNP levels in 
plasma reflect the stretch and tension of the myocardial wall 18. This stretching of 
ventricular myocytes cause the production and release of the cardiac natriuretic hormones 
8. Plasma BNP and NT pro-BNP levels are also elevated in patients with pulmonary 
hypertension 19, in patients with renal dysfunction 20 in addition to patients with and 
without CHF who exhibit a high body mass index 21.  
 High levels of BNP and NT pro-BNP identify patients at greatest risk of future 
cardiovascular events, including death 22, but BNP and NT pro-BNP can not replace 
information obtained from echocardiography and invasive hemodynamic monitoring 18. 
Adjusting medical therapy in patients with CHF in order to reduce natriuretic peptides 
levels may improve outcome 23. In addition, exercise training may lead to a decrease in 
BNP and NT pro-BNP levels 24. However, there are controversial results regarding the 
effect of exercise training on BNP and NT pro-BNP in patients with CHF 24-28. 
 
Exercise training in patients with chronic heart failure 
Patients with CHF have 30-50% reduced functional capacity as compared with age –
matched healthy subjects 2,29. A reduced functional capacity have shown to result in 
lower HRQL 30. 
 Until the 1990s, CHF was described as a condition best treated by rest, and 
patients with CHF were excluded from exercise training due to concerns of safety and 
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beneficial effects in an already damaged myocardium 31,32. By contrast, the latest 
guidelines for diagnosis and treatment of CHF from the American Heart Association 33 
and ESC 3,34, recommend exercise training for all patients with stable CHF. A number of 
studies from the last decades have led to this change in treatment approach 35-42.  
 Exercise training has been shown to be well tolerated in patients with stable CHF 
and has been shown to result in improved functional capacity and HRQL 42. Evidence 
suggests that these benefits mainly are due to the effects of exercise training on peripheral 
skeletal muscles and circulation rather than on the myocardium 43. In addition, exercise 
training has been shown to improve the ratio of type 1 and type 2 muscle fibers in 
skeletal muscles 44, partially reverse activation of the neurohormonal system, reduce 
levels of pro-inflammatory cytokines 44, reduce dependence on anaerobic metabolism 34, 
improve skeletal muscle metabolism 45,  and increase blood flow within the active 
skeletal muscles 46. There is limited evidence to support the contention that exercise 
training can lead to a reduction of mortality and morbidity in patients with CHF.  Most of 
the studies employ a small sample size too small to be able to distinguish between no 
effect and a reduction of 20% in cardiovascular related mortality. A meta analysis by the 
ExTraMATCH Collaborative group 47 found that exercise training reduced mortality, 
morbidity and hospital admissions. The results of the ongoing HF-ACTION Trial 48 (an 
international, multi-centre, randomized trial) will provide long-awaited information about 
the effects of exercise training on mortality and morbidity in patients with CHF 
(EF<35%) in NYHA class II-IV. 
 There is no general agreement on exercise training mode or intensity for patients 
with CHF, probably due to the variation in the studies included in the exercise guidelines 
  6 
2,34. The exercise training mode vary considerably in the literature and cycle ergometer 
and treadmills are most frequently used in exercise training programs 47. Furthermore, 
individual tailored exercise training at moderate intensity are most frequently included in 
the previously published studies 39,42,49-53. Research on an exercise training mode often 
used in Scandinavian hospitals and cardiac rehabilitation centre, group-based aerobic 
interval training (see Paper I) is limited. Recent research, however, suggest greater 
functional capacity and cardiovascular adaptations result from high intensity exercise 
training compared to low/moderate intensity both in healthy subjects 54, and in patients 
with CAD 55 and CHF 45.  
 Cardiac rehabilitation is described as an interdisciplinary intervention aimed at 
improving functional capacity, as well as psychological and social conditions affecting 
people with chronic or post-acute heart disease 56,57. Exercise training therefore needs to 
include group and/or individual counseling to target the patients’ psychological and 
social conditions 57. Patients with CHF have a poorer HRQL than other common chronic 
conditions such as diabetes and chronic lung disease 58. In accordance with the severity of 
symptoms in patients with CHF, patients develop severe psychological disorders, such as 
anxiety and depression 59. There is conflicting evidence on the effect of exercise training 
on HRQL in patients with CHF 26,42, and no changes in HRQL were observed in the 
EXERT trial 60. Therefore, HRQL should be included in an evaluation of exercise 
training programs for patients with CHF. 
 The overall aim of the exercise training is to encourage patients to maintain a 
physical active lifestyle following the exercise training prescription (exercise adherence). 
However, studies of exercise training for patients with CHF lack attention to the issue of 
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exercise adherence in these patients 61. Only a few studies have evaluated exercise 
adherence in the long term (>12 months). An important factor by adherence to exercise 
training is to increase the patients self-efficacy 61. Self-efficacy is a part of Bandura´s 
social learning theory 62, and it is characterized by four main components; observation of 
others, persuasion by an authority, successful performance of the behavior and 
physiologic feedback.  
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AIMS OF THE STUDY 
 
The overall aim of the work presented in this thesis was to evaluate the effect of the 
Norwegian Ullevaal model (group-based high-intensity aerobic interval training 
including counseling) in patients with CHF on functional capacity, quality of life and 
circulating levels of NT pro-BNP. To achieve this, we evaluated the feasibility and 
effects of the Norwegian Ullevaal model and designed a randomized controlled trial, 
following patients with CHF for 12 months.  
The specific aims were: 
Paper I 
 • To describe the Norwegian Ullevaal model for patients with CHF in  
  NYHA class III. 
 • To evaluate if the program was feasible for this patient group, and to  
  describe how the program was developed and implemented as an   
  interdisciplinary treatment program. 
 
Paper II 
 • To evaluate the effect of the Norwegian Ullevaal model on functional  
  capacity in patients with CHF, compared to a control group who received  
  standard care.  
 • To evaluate the differences in HRQL in patients with CHF who had  
  received the intervention program compared to the control group. 
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 • To examine the relationship between changes in functional capacity and  
  HRQL.  
 
Paper III 
 • To evaluate the long-term effect (12 months follow-up) of the Norwegian  
  Ullevaal model on functional capacity and HRQL in patients with CHF  
  compared to a control group. 
 
Paper IV 
 • To evaluate the effect of the Norwegian Ullevaal model on circulating  
  levels of NT pro-BNP in patients with CHF.  
 • To examine the relationship between NT pro-BNP and functional   
  capacity. 
 
 
 
 
 
 
 
 
 
 
  10 
MATERIAL AND METHODS 
 
Four papers were included in this thesis. Paper I is a case report and Papers II, III and IV 
are randomized controlled trials based on data from one study sample. 
The majority of the protocol is presented in Paper II, and the Norwegian Ullevaal model 
is in detail described in Paper I. Therefore, the protocol is only briefly described. 
 
Patients 
From September 2001 until February 2004, 80 patients (63 men and 17 women), with 
CHF in NYHA class II-IIIB, were included. All patients who were referred to the heart 
failure out-patient clinic at Ullevaal University Hospital (UUH) in Oslo, and who met the 
inclusion criteria, were invited to participate in the study. In addition from September 
2003, we invited patients from the heart failure out-patient clinic at Lovisenberg Hospital, 
Oslo, into the study.  
 Prior to assess them for eligibility to the study (screening), all patients had been 
titrated to maximal tolerable doses of medical treatment at the heart failure out-patient 
clinic (standard care). After optimal medical treatment, all patients underwent a six 
minute walk test (6MWT) as a screening test before inclusion. After baseline testing, 
patients were consecutively randomized to either the exercise group or the control group 
by a permuted block randomization (the block size was 4), provided by Center for 
Clinical Research at UUH (Figure 1). The four patients described in the case report 
(Paper I) were four random patients with CHF in NYHA class III who were included in 
the intervention group of the study.   
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Inclusion criteria: 
- Stable CHF (for four weeks). 
- Left ventricular ejection fraction (EF) < 40% or,  
- EF   40% with clinical symptoms of heart failure (preserved EF). 
- Age between 20 and 85 years. 
 
Exclusion criteria: 
- Acute myocardial infarction within four weeks. 
- Unstable angina pectoris.  
- Serious rhythm disturbances. 
- Symptomatic peripheral vascular disease. 
- Obstructive pulmonary disease with forced expiratory vital capacity > 50% of 
predicted. 
- 6MWT > 550 m, and workload on the cycle ergometer test >110 W.  
- Known significant comorbidity that would prevent entry into the study due to 
known terminal disease or inability to exercise (e.g. severe musculoskeletal 
disorder, advanced valvular disease). 
- Long-term care establishment. 
 
The study was approved by the Regional Committee for Medical Research Ehtics and by 
the Norwegian Data Inspectorate. All patients gave their written informed consent to 
participate after receiving verbal and written information.  
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Figure 1. Flowchart 
 
 
 
              Assessed for eligibility (n=95)  
Excluded  (n=15) 
Not meeting inclusion criteria (n=5) 
Refused to participate (n=10) 
Discontinued (n=3) 
Death (n=2) 
Refused repeated testing (n=1) 
Intervention Group (n=40) 
32 hours exercise and  
4 hours individual counseling 
 
Discontinued (n=2) 
Unwilling to accept 
randomization group (n=1)     
Because of sudden death (n=1) 
Control Group  (n=40) 
Usual care without  
supervised exercise 
 Randomization 
           (n=80) 
Discontinued  (n=2) 
Without reason (n=1) 
Stroke (n=1) 
Outcome measurements (T2) 
6MWT, cycle ergometer test, 
MLHFQ, NT pro-BNP 
Baseline testing (T1): 
6MWT, cycle ergometer test, 
MLHFQ, NT pro-BNP 
Outcome measurements (T3) 
6MWT, cycle ergometer test, 
MLHFQ, NT pro-BNP 
  12 months 
  Follow-up 
  4 months 
  Follow-up 
2 hours individual counseling 
Discontinued (n=1) 
Refused repeated testing (n=1) 
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The Norwegian Ullevaal model 
The Norwegian Ullevaal model consist of a group-based exercise training program 
including simple aerobic dance movements. The exercise training program is guided with 
music and includes endurance, strength, flexibility and stretching exercises in addition to 
group-based and individual counseling (Paper I). It is an interval training program with 
three intervals of high intensity (15-18 on Borg scale 63). The total duration of the 
exercise training part is 50 minutes (Figure 2). 
 
 
Figure 2. A schematic illustration of the group-based aerobic interval-training program. 
The duration is 50 minutes of exercise plus 15 to 30 minutes of counseling. The figure 
shows three peaks of high intensity (VO2). The intensity is adjusted using the Borg 
Scale and beats per minute (BPM) of the music pace. Coordination exercises were 
included throughout the program.  
VO2 = oxygen consumption, Flex= flexibility exercises. 
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 The group-based counseling part lasted from 15-30 minutes, depending on the 
patients’ needs. The program was offered twice a week for a total of 32 exercise sessions. 
Patients had up to six months to complete the 36 sessions before the post exercise test 
(T2) took place. In addition the patients were offered four individual counseling visits 
with a CHF nurse, during the exercise training part in addition to two counseling visits 
during the follow-up (12 months).   
 The aim of the exercise training intensity was to achieve a heart rate (HR) of 90-
95 % of the maximum HR (HRmax) achieved on the cycle ergometer test at baseline. A 
typical HR curve during an exercise training session is shown in Figure 3.  
 
 
Figure 3. Example of a patient heart rate (HR) during one exercise training session. This 
patients HRmax was 129 beats/min during the cycle ergometer test at baseline. HRmax 
during the exercise training session was 124 beats/min (96% of achieved max). Average 
heart rate was 102 beat/min (79% of achieved HRmax). 
 
 
A detailed description of the Norwegian Ullevaal model is presented in Paper I, including 
appendixes of exercises (Paper I, Appendix 1.) and music pace (Paper I, Appendix 2. and 
3.). 
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Outcome measurements 
All measurements were obtained at baseline (T1) and repeated after intervention (mean 
22 ± 3.8 weeks) (T2) and after the12 month follow-up (mean 54.3 ± 2.8 weeks) (T3). The 
statistical analyses are described in the respective Papers (II, III, IV) and will only briefly 
be mentioned here. 
 
Six minute walk test 
Functional capacity was assessed as the distance walked during a 6MWT 64. The 6MWT 
was performed in a 125 m pre-marked hospital corridor. The patients were instructed to 
walk from end to end at their own pace, attempting to cover as long distance as possible 
within six minutes. Stops and rests were allowed, if needed, and standard 
encouragements were used after three minutes (“you are doing well, and you have three 
minutes left”). The first 6MWT was performed at screening to select the right population 
(6MWT  550 m) and to familiarize the patients with the procedure. A second 6MWT 
was performed at baseline. A physical therapist (B.B.N.), or one of the three study nurses 
performed all screening and baseline tests. Three other physical therapists and three other 
nurses who were blinded to the clinical data and group assignment of the patients carried 
out all the follow-up tests. The 6MWT has demonstrated an ability to provide valid and 
reliable 65 information of functional capacity for patients with CHF 66.  
 
Cycle ergometer test 
The patients maximal exercise time and workload were evaluated on an electrically 
braked cycle ergometer (Ergometrics 800, Ergoline, Bitz, Germany). The work was 
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performed in the sitting position and a 12 lead ECG was recorded continuously during 
exercise, and for five minutes after work. We used a test protocol with an initial load of 
30 W lasting for one minute, whereupon the load was increased step-wise by 10 W/min 
until exhaustion or a reported perceived exertion (RPE) on the Borg scale 63 of 17-18 67. 
Heart rate (HR) was measured from the ECG, and auscultatory systolic blood pressure 
was measured on the right arm every third minute. The total exercise time in seconds and 
the maximal work load the patients maintained for 60 seconds were recorded. For 
patients with CHF, stage increments of 10 to 15 watt every minute during the cycle 
ergometer test have been recommended 68.  
 
Health related quality of life 
HRQL was assessed using the Minnesota Living with Heart Failure Questionnaire 
(MLHFQ) 69. In clinical trials and clinical practice, the MLHFQ is the most frequently 
used disease-specific measure of HRQL in studies with CHF patients 4,70. The 
questionnaire is a 21-question self-assessment questionnaire with a maximum score of 
105. The higher the score the lower the HRQL. The MLHFQ has been shown to be a 
valid 69 and reliable 69,71 disease-specific measure of HRQL in patients with CHF. 
 
Blood samples 
Venous blood samples were taken at rest between 8 and 9 am, in a sitting position, after 
overnight fasting (before intake of medication) and measured with standard procedures at 
UUH, Oslo, Norway. NT pro-BNP was measured in EDTA-plasma with the Elecsys 
proBNP sandwich immunoassay on Elecsys 2010 (Roch Diagnostics). The inter-assay 
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coefficient of variation in our laboratory was 7 %. NT pro-BNP samples were stored at -
80°C until analyses were performed. 
 
Sample size calculation and statistical analysis 
A clinically important effect of exercise training was estimated to be a difference 
between groups of 50 meters on the 6MWT from baseline to post exercise test. With a 
significance level (Type I error or ) of 5%, a Type II error or  of 20%, which indicates 
a statistical power of (1- ) 80%, and an estimated SD of the 6MWT of 90 m, it was 
calculated that 37 patients were needed in each group. To allow for some drop-outs, it 
was decided to include a total of 80 patients. In Paper II and Paper III, data were analyzed 
and presented according to intent to treat (ITT) principle. The statistical methods used are 
presented specifically in each paper. The effect sizes (Paper II and III) were interpreted 
according to Cohen`s index 72, where 0.2 refers to a small change, 0.5 to a moderate 
change and 0.8 and above to a large change. 
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SUMMARY OF RESULTS 
 
Paper I 
This Paper described the background, the mode and the intensity of the Norwegian 
Ullevaal model, which was developed at and clinically used for patients with CAD for 
three decades, at UUH. The Norwegian Ullevaal model is used as intervention in Paper 
II, III and IV. Paper I is written as a case report, with four male patients with CHF in 
NYHA class III who were randomly selected from the intervention group in the study 
population. 
 The patients increased their 6MWT distance with 117, 66, 135 and 143 m, 
respectively. Patient 1,2, and 3 increased their time on the cycle ergometer test with 17, 
25 and 52 %, respectively. Patient 4 did not complete the cycle ergometer test due to his 
pacemaker. The patients increased their MLHFQ with 42, 8, 18, 53 points, respectively. 
There were no complications related to the exercise training and no adverse events. 
 
Paper II 
This Paper presented the main results of functional capacity and HRQL measurements in 
the intervention group and the control group before and after the four months (22± 3.8 
weeks) intervention period (from T1 to T2). A total of 80 patients were included in the 
study.  
 There were no complications of any kind during exercise testing or the exercise 
training. The average compliance (actually performed exercise training sessions divided 
by possible sessions) in the intervention group was 95%. Only one patient did not give 
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any reason for drop-out. There were no significant differences between groups regarding 
patients’ baseline characteristics, with a mean age of 70 ± 8 years and an EF of 30.2 ± 7.6 
%. There were no significant differences between groups in functional capacity at 
baseline, but the MLHFQ score was significantly higher (worse) in the intervention group 
compared to the control group. After the intervention (mean 22± 3.8 weeks), functional 
capacity improved significantly in the intervention group compared to the control group 
for all measurements (6MWT; +58 m versus -14 m., p< 0.001, cycle ergometer test; +10 
W versus -1 W, p< 0.001 and, 57 sec versus -8 sec, p< 0.001). HRQL improved 
significantly in the intervention group compared to the control group (p=0.03), and a 
significant inverse correlation was found between delta MLHFQ and delta 6MWT (r=-
0.49, p<0.05). 
 
Paper III 
This Paper presented the long-term results of the Norwegian Ullevaal model on 
functional capacity and HRQL assessments (same population as Paper II). After 12 
months (mean 54.3 ± 2.8 weeks) the improvements were still significant for all the 
outcome measurements in the intervention group compared to the control group. (6MWT; 
41 m versus -20 m, p<0.001, work load; +10 W versus -1 W, p=0.001, exercise time; 53 
sec versus -6 sec, p=0.003, and MLHFQ; 10 points improved versus 6 points worse, 
p=0.003). 
 
Paper IV 
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This Paper summarized the changes in NT pro-BNP over time (same population as Paper 
II and III). Available blood samples at baseline were 78, at T2; 70, and at T3; 69. There 
were no significant changes in NT pro-BNP levels between groups from baseline to 
either T2 or T3. No significant correlation between change in NT pro-BNP and change in 
functional capacity (6MWT; r=0.12, p=0.33, Exercise time; r=0.04, p=0.72) was 
observed in the whole study population. 
 There was a significant inverse correlation between NT pro-BNP and 6MWT (r= -
0.24, p=0.035) and between NT pro-BNP and exercise time (r=-0.48, p< 0.001) at 
baseline.  
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GENERAL DISCUSSION 
 
Subjects 
A total of 80 patients participated in this study. The subjects included in the study need to 
be a representative selection of the population of patients with CHF in order to generalize 
the results from this single trial to a larger population 73. All patients in the present study 
were informed that they had to be willing to exercise twice a week for four months if 
allocated to the intervention group, even though we did not know, before completing the 
study, what the effect of the Norwegian Ullevaal model would be. All patients admitted 
to the heart failure out-patient clinic were screened for inclusion in the study, but we did 
not register the patients who did not satisfy the inclusion criteria. Some patients where 
excluded due to walking aids. Most of the patients were excluded due to a walking 
distance of above 550 meters during the 6MWT. The results of the present study are 
therefore valid for a population of patients with CHF in NYHA- class II-IIIB, who are 
between 45 and 85 years, who walk without the use of walking aids and who walk a 
distance during the 6MWT of < 550 meters.  
 The prevalence of CHF increases with age, but the majority of patients included 
in previous studies of an exercise training intervention, was of a younger age than our 
population 39,42,52,74-76. During the last decade, pharmacological therapy of CHF has 
involved the use of beta-blockers. However, data are limited regarding exercise training 
intervention in patients with CHF who are on optimal medical treatment. In our study, all 
patients were on optimal medical treatment and more than 90 % were treated with beta-
blockers. 
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Design  
The randomized controlled trial is considered the gold standard design when assessing 
the effect of treatments (Paper II, III, IV) 73. Random allocation, cover of allocation, 
blinding and the lack of patients´ attrition to the intervention protocol are considered the 
most important methodological factors to ensure a high internal validity. It is not possible 
to blind patients to an exercise training intervention, but the follow-up tests (T2 and T3) 
were assessed by blinded test persons and the patients were told not to reveal to which 
groups they belonged at follow-ups. Case reports (Paper I), describe various aspects of 
clinical practice but do not test hypotheses, establish cause-and-effect relationships, or 
prove effectiveness 77. A Case report design for Paper I was chosen to be able to 
thoroughly describe and discuss the Norwegian Ullevaal model, an interdisciplinary, 
group-based program that have never previously been described in the literature. 
 
The Norwegian Ullevaal model 
Group-based and interdisciplinary program 
Most exercise training studies have included individual based or home-based exercise 
training programs for patients with CHF. During the three last decades we have acquired 
substantial knowledge and extensive experience with the Norwegian Ullevaal model used 
as an exercise training program for patients with cardiac disease at UUH. There existed a 
need, therefore, to first describe our program (Paper I), and secondary to evaluate (Paper 
II, III and IV) our program in respect to the feasibility of its use, and its short and long-
term effects on patients with CHF.  
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 The literature has described the advantage of using a group-based exercise 
training program 78-80. The individuals experience and sense of belonging, feeling 
supported and learning from each other are beneficial. All these factors seem to be of 
importance regarding enhance commitment 79. Positive feedback, perception of success, 
and expectation of success are important for compliance and adherence to an exercise 
training program 61. The Norwegian Ullevaal model benefits from the interactive and 
social components described by Bandura`s social learning theory, but the program 
requires the skills and knowledge of a professional instructor (physical therapist) to 
conduct the exercise training 81. Another advantage of a group-based exercise training 
program is that it is not expensive and does not require any sophisticated equipment. 
However, there is a need for additional studies to evaluate the cost-benefit effects of a 
group-based program compared to other programs. Since this program was performed in 
an out-patient clinic, it might be thought of as a useful “beginner”- program to prepare 
patients with CHF to exercise on their own. 
 The use of an interdisciplinary program makes it difficult to separate the 
effect of the group-based exercise training and counseling from the individual counseling 
with the nurse. This study examined the effect of the whole program, and we are not able 
to say which aspect is the most significant. But, patients with CHF usually have several 
comorbidities and polypharmacy, and are probably most likely to benefit from such an 
interdisciplinary program, including individual counseling.  
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Intensity 
Exercise training intensity can be expressed as a percentage of HR or maximal oxygen 
uptake (VO2max) or rate of perceived exertion (RPE) 82 (Table 2). The term peak oxygen 
uptake (VO2peak) is the highest rate of oxygen consumption measured during the exercise 
test, regardless of whether or not a VO2 plateau was reached. VO2peak is more commonly 
used in patients with CHF due to inability to achieve the VO2max criteria 83.  
 
Table 2. Classification of intensity during physical activity.  
Adapted from American College of Sport Medicine 82. 
 
Relative intensity/ 
Perception of effort 
HRmax % VO2max % RPE 
Very light < 35 < 20 < 10  
Light 35-54 20-39 10-11 
Moderate 55-69 40-59 12-13 
Hard 70-89 60-84 14-16 
Very hard 
 90  85 17-19 
Maximal 100 100 20 
 
HRmax= maximal heart rate, VO2max = maximal oxygen consumption, RPE=Rate of 
perceived exertion (Borg scale 6-20 63). 
 
There is no consensus on exercise training intensity for patients with CHF because the 
great variation displayed by the studies prevents the formation of a basis upon which 
recommendations could be built. The latest recommendations for exercise training in 
CHF patients from the ESC working group (2001) state that patients with CHF should 
exercise at moderate to high intensity (40-80% of VO2peak) 68. In the latest statements 
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from American Heart Association Committee on exercise, rehabilitation, and prevention 
(2003) it is reported that the most frequently used exercise training intensity range from 
70% to 80% of VO2peak. Furthermore, they stated, based on one article 84, that exercise 
training intensity during interval training did not seem to influence the magnitude of the 
increase in functional capacity 2.   
 In contrast, high-intensity aerobic interval training is reported to be, in recent 
studies, twice as effective as low-moderate exercise training with respect to improving 
VO2peak in patients with CAD 55, patients with CHF 45 and in healthy subjects 54. When 
the total volume of exercise training is held constant, more vigorous exercise training 
seems to provide greater health benefits than moderate exercise training 85. Aerobic 
interval training allows patients with compensated CHF to complete short, but high 
intensity, exercise training periods that would not be possible with a continuous exercise 
training program 86,87.  In our exercise training program the average intensity was 
between 70-80 % of the HRmax at baseline (Figure 2). Thus the total cardiac work was not 
necessarily higher than in continuous exercise training programs, even though the 
intensity was high (90-95% of the HRmax) during the three interval-peaks. 
 
Outcome measurements 
Functional capacity - 6MWT and cycle ergometer test 
The 6MWT has been used as an end-point for examining functional capacity in several 
clinical trials in patients with CHF 88. It is a well tolerated and an inexpensive alternative 
method to evaluate functional capacity and probably more representative of the 
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individuals capacity during daily activities, compared to maximal exercise testing 
methods 66,89,90.  
 Testing of submaximal exercise using the 6MWT appears to be a more sensitive 
indicator of a training effect than maximal cardiopulmonary exercise tests 89. In addition, 
the walking distance assessed by the 6MWT has been shown to be significantly related to 
VO2peak (p<0.001) 91,92, and to represent an independent predictor of mortality and 
morbidity in patients with CHF 93,94. 
 The patients in our study had a mean walking distance during the 6MWT of 456 
meters at baseline. This is in accordance to some other studies 89-91, but in most studies 
that have included the 6MWT as an endpoint, the patients have covered a much shorter 
walking distance at baseline (mean 266-385 m) 27,49,95-98. The 6MWT in healthy, age 
matched subjects range from 400-700 m 99. However, the walking distance varies by up 
to 30% between the few published studies 99. One explanation for the high walking 
distance during the 6MWT in our population could be that the Norwegian population is 
familiar with physical activity and seems to have a high fitness level 89 compared to other 
populations from other countries. In addition, differences in the length of the hallway 
used during the 6MWT, resulting in more or less turns, may also affect the covered 
walking distance during the 6MWT. 
 VO2peak is considered to be the gold standard for evaluating functional capacity in 
patients with CHF 100. We did not have the equipment or personnel to perform this test at 
the Department of Cardiology at the moment we designed the present study. However, 
the improvement in the 6MWT in the intervention group was in our study complemented 
by the significant improvements in workload and exercise time during the cycle 
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ergometer test. The patients performed the cycle ergometer test using a stepwise increase 
in workload (10 W/min) until volitional exhaustion was reached (Borg scale 17-18). A 
protocol of equal amount each minute is suitable for patients with CHF 101 and has been 
used at our hospital over the last decades. Functional capacity measurements (VO2peak, 
maximal cycle work rate and 6MWT) have shown to correlate significantly with one 
another. Maximal cycle work rate has shown to correlate significantly with VO2peak 
(r=0.85) in a study with a similar baseline walking distance during the 6MWT (448 m) 
and using the same cycle ergometer protocol as in our study102. 
 
Health related quality of life 
HRQL is a widely used outcome measure in randomized controlled trials of exercise 
intervention, and a number of disease-specific questionnaires for CHF have been 
developed 70. There are mainly two different types of HRQL measurements used in 
studies with CHF patients: generic and disease-specific questionnaires. Generic 
questionnaires aim to provide a summary of HRQL, irrespective of the disease or the 
condition of the patient. Disease-specific questionnaires focus on the difficulty 
experienced by the specific patient group or by individuals in specific disease states 103. 
In Paper I, II and III, HRQL was evaluated with the disease-specific questionnaire, 
MLHFQ. Considering its widespread use in exercise intervention studies 104, the MLHFQ 
was the clear choice. At our hospital we have extensive experience with the MLHFQ, due 
to its simplicity, and the fact that it is easily understood for older patients. The MLHFQ is 
a valid and reliable measurement of HRQL in patients with CHF 69. Similar to results 
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from the EXERT trial 60, the patients in our study had a relatively low score of the 
MLHFQ (mean 27.5) compare to other studies on patients with CHF 53,96,105.  
 
N-terminal pro B-type natriuretic peptide  
Neurohormonal activation is a hallmark of CHF 106. In recent years there have been 
several studies which have focused on the clinical usefulness of circulating markers in 
patients with CHF 7,107. There may be some advantage in NT pro-BNP measurements 
compared to BNP, mainly because plasma BNP is relatively more labile than NT pro-
BNP 108. BNP analysis is sensitive to temperature change and is also affected by the type 
of tube that blood is collected in. This is in contrast to NT pro-BNP who is not subject to 
those types of measurement errors 18. 
 
Statistics 
In the present study, ANCOVA was used to assess end points between groups from 
baseline to follow-up measurements (Paper II, III and IV). ANCOVA adjusts for possible 
baseline differences and is considered a more powerful analysis than alternative methods 
like Student t-tests and ANOVA 109,110. The main statistical limitation of the study is the 
relative low statistical power in Paper IV. 
 ITT analysis was used in Paper II and III. The primary analysis of a randomized 
controlled trial should always include ITT analysis, since it avoids the possibility of any 
bias associated with lost to follow-up or because of non-adherence of patients in the 
study. ITT with last value carried forward was used in case of missing values. Conducted 
both by per protocol analysis and by ITT, these analyses resulted in similar values.  
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Results 
The main findings in this study demonstrated that patients with CHF in NYHA-class II-
IIIB significantly improved their functional capacity and HRQL (Paper II and III) by 
participating in the Norwegian Ullevaal model compared to a control group. In addition, 
the improvements were still significant after 12 months. Despite randomization, the 
baseline scores regarding HRQL were worse in the intervention group. This was taken 
into consideration by including ANCOVA analysis when conducting comparisons 
between group differences of follow-up measurements (T2 and T3). 
 The compliance with the exercise training (actually performed exercise training 
sessions divided by possible sessions) in the present study was high (95%). High 
compliance was probably achieved due to; the opportunity to extend the total number of 
exercise training periods to 24 weeks; the opportunity of meeting other patients with the 
same kind of problems; the individual counseling with the CHF nurse; the physical 
therapists ability to make exercise safe and motivating and the collegiality that developed 
among patients and the encouragements and support they provided to each other. The 
non-existence of complications or any cardiac events during the exercise training may be 
seen as evidence of the safety of the program.  
  
Why is this the first study to document sustained effects of exercise training in patients 
with CHF? 
  
It is well known that the favorable adaptations obtained after prolonged exercise training 
disappear rapidly when a person stops exercising 111. Several studies of the physiological 
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variables with different duration of detraining confirms this observation in athletes 112, as 
well as in patients with CAD 113,114 and patients with CHF 115.  We have no data on 
physical activities between the post intervention test (T2) and the 12 month follow-up 
(T3) (exercise adherence data). Nevertheless, a significant difference between the groups 
at the 12 month follow-up (with no significant loss of functional capacity) indicated that 
the patients in the intervention group had been more physically active than the control 
group.  
 Adherence to an exercise training program depends almost entirely on the patients 
motivation 116. The main objective for the physical therapist (instructor) is to make the 
program motivating and meet the individual’s needs. An important factor when 
counseling patients in exercise training is the skill and knowledge of the physical 
therapist to transfer feeling of safety and joy about exercise training 29,117. The main 
reason for drop-outs from exercise training programs is the monotony of the exercise 
training regime 116. With a skilful physical therapist as instructor for the exercise training, 
the Norwegian Ullevaal model will never be monotone. Informal comments from the 
patients in the intervention group indicated that they found it enjoyable and motivating to 
exercise with music and varied intensity. Informal comments indicate that the high 
intensity exercises in this program could lead patients to dare to continue exercise 
training on their own. In addition, some patients continued a group-based exercise 
program in their home districts. Their family also found it safe to accompany relatives 
with CHF on a brisk walk because they had been informed of the high intensity aspect of 
the exercise training program. This observation stands in contrast to studies that evaluate 
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exercise training and find that high-intensity is associated with a lower adherence to 
exercise training than a lower-intensity 118,119.  
 Table 3 summarizes interventions and results of randomized controlled trials with 
follow-up  10 months. To our knowledge, the present study is the only study that 
showed improved long-term effects of exercise training on functional capacity and 
quality of life in patients with CHF. Exercise adherence rates decrease as trial duration 
increase 61. Two studies followed the patients for six 75 and five 120 years. These two 
studies could not be compared to the others 60,74,95,121,122. All the studies (in Table 3) 
included interventions at a lower exercise training intensity compared to the program of 
high-intensity in our study. Most of the studies offered a rather monotone exercise 
training program with either walking or ergometer cycle. Our results suggest that the 
intensity of the exercise training in the Norwegian Ullevaal model may be an important 
factor for the improved functional capacity and HRQL and also the long-term effect. 
Another important consideration is the selection of activities that the patients enjoy. All 
these factors may be significant for the prolonged effect of the Norwegian Ullevaal 
model.      
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 Our data did not support the notion that neurohormonal status would improve as a 
result of exercise training in stable patients with CHF (Paper IV). This observation is in 
line with a recently published observational study 27, but stands in contrast to previous 
studies 24,25,123. However, we found a significant correlation between NT pro-BNP and 
functional capacity at baseline, in line with previous reports 7,24,27.  
 In recent years, several studies have studied the relationship between 
improvement in functional capacity and change in levels of NT pro-BNP 24,25,123 or BNP 
26,28,124. The studies differ largely in design, duration and mode of exercise training, as 
well as in the outcome variable as measure of neurohormonal burden, BNP and NT pro-
BNP. Exercise training in patients with CHF has been shown to primarily affect 
peripheral working muscles 125,126, which may not cause an effect on the NT pro-BNP 
levels. Our study population was on optimal medical treatment and the levels of NT pro-
BNP in the present study were relatively low (median 188 pmol/l) compared to other 
studies 24,25,123, and reduced levels would possibly be difficult to obtain.  
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CONCLUSIONS 
 
• The Norwegian Ullevaal model is feasible and improves functional capacity and 
 quality of life in patients with CHF, both in the short and the long-term. 
 
• The Norwegian Ullevaal model is safe and there is no need for costly equipment 
 for monitoring patients. In addition, the program can be performed with a high 
 compliance rate in patients with CHF. 
 
• The Norwegian Ullevaal model does not support improvement in neurohormonal 
 status, as no significant reduction in plasma levels of NT pro-BNP was 
 observed. 
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